Amplification of Cerenkov luminescence using semiconducting polymers for cancer theranostics.
Cerenkov radiation
Semiconducting polymers
cancer theranostics
drug delivery
multimodal imaging
nanomaterials
positron emission tomography
Journal
Advanced functional materials
ISSN: 1616-301X
Titre abrégé: Adv Funct Mater
Pays: Germany
ID NLM: 101190390
Informations de publication
Date de publication:
15 Aug 2023
15 Aug 2023
Historique:
pmc-release:
15
08
2024
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
ppublish
Résumé
The therapeutic efficacy of photodynamic therapy is limited by the ability of light to penetrate tissues. Due to this limitation, Cerenkov luminescence (CL) from radionuclides has recently been proposed as an alternative light source in a strategy referred to as Cerenkov radiation induced therapy (CRIT). Semiconducting polymer nanoparticles (SPNs) have ideal optical properties, such as large absorption cross-sections and broad absorbance, which can be utilized to harness the relatively weak CL produced by radionuclides. SPNs can be doped with photosensitizers and have nearly 100% energy transfer efficiency by multiple energy transfer mechanisms. Herein, we investigated an optimized photosensitizer doped SPN as a nanosystem to harness and amplify CL for cancer theranostics. We found that semiconducting polymers significantly amplified CL energy transfer efficiency. Bimodal PET and optical imaging studies showed high tumor uptake and retention of the optimized SPNs when administered intravenously or intratumorally. Lastly, we found that photosensitizer doped SPNs have excellent potential as a cancer theranostics nanosystem in an in vivo tumor therapy study. Our study shows that SPNs are ideally suited to harness and amplify CL for cancer theranostics, which may provide a significant advancement for CRIT that are unabated by tissue penetration limits.
Identifiants
pubmed: 37942189
doi: 10.1002/adfm.202302777
pmc: PMC10629852
mid: NIHMS1902660
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA014520
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009206
Pays : United States
Déclaration de conflit d'intérêts
Conflict of Interest Weibo Cai declares conflict of interest with the following corporations: Actithera, Inc., Rad Source Technologies, Inc., Portrai, Inc., rTR Technovation Corporation, and Four Health Global Pharmaceuticals, Inc. All other authors declare no conflict of interest.
Références
Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):508-524
pubmed: 36222853
Chem Rev. 2012 Aug 8;112(8):4687-735
pubmed: 22670807
Philos Trans A Math Phys Eng Sci. 2011 Nov 28;369(1955):4605-19
pubmed: 22006909
Cancer Biother Radiopharm. 2009 Aug;24(4):379-93
pubmed: 19694573
Nanoscale. 2011 Apr;3(4):1451-5
pubmed: 21293789
Nat Nanotechnol. 2014 Mar;9(3):233-9
pubmed: 24463363
J Nucl Med. 2011 Dec;52(12):2009-18
pubmed: 22080446
ACS Nano. 2008 Nov 25;2(11):2415-23
pubmed: 19206410
Adv Mater. 2012 Jul 10;24(26):3498-504
pubmed: 22684783
J Nucl Med. 2007 Jun;48(6):932-45
pubmed: 17504879
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916
Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):60-9
pubmed: 24380046
J Am Chem Soc. 2018 Nov 7;140(44):14971-14979
pubmed: 30336003
Langmuir. 2006 Mar 28;22(7):2956-60
pubmed: 16548540
Nat Nanotechnol. 2017 Feb 7;12(2):106-117
pubmed: 28167827
Angew Chem Int Ed Engl. 2013 Mar 11;52(11):3086-109
pubmed: 23307291
Angew Chem Int Ed Engl. 2019 Sep 16;58(38):13232-13252
pubmed: 30779286
Nat Commun. 2018 Jan 18;9(1):275
pubmed: 29348537
J Control Release. 2016 Oct 28;240:312-322
pubmed: 26773769
Nat Nanotechnol. 2018 May;13(5):418-426
pubmed: 29581551
Theranostics. 2021 Jun 22;11(16):7735-7754
pubmed: 34335961
Chem Rev. 2020 Apr 22;120(8):3787-3851
pubmed: 32202104
J Am Chem Soc. 2014 Feb 5;136(5):1706-9
pubmed: 24401138
J Am Chem Soc. 2010 Mar 24;132(11):3989-96
pubmed: 20175539
Phys Med Biol. 2009 Aug 21;54(16):N355-65
pubmed: 19636082
Nat Biotechnol. 2017 Nov;35(11):1102-1110
pubmed: 29035373
J Phys Chem C Nanomater Interfaces. 2008 Feb 14;112(6):1772-1781
pubmed: 19221582
J Phys Chem B. 2005 May 12;109(18):8543-6
pubmed: 16852006
Am J Nucl Med Mol Imaging. 2012;2(2):163-73
pubmed: 23133811
EJNMMI Phys. 2017 Dec;4(1):14
pubmed: 28283990
Nat Nanotechnol. 2015 Apr;10(4):370-9
pubmed: 25751304
ACS Appl Mater Interfaces. 2016 Oct 12;8(40):26630-26637
pubmed: 27657487
Nat Med. 2013 Oct;19(10):1345-50
pubmed: 24013701
Biomaterials. 2018 Feb;155:217-235
pubmed: 29190479